WATCH: Gene editing and advanced therapies—patent strategies for the next generation of precision medicine

David Longmuir and Danielle Burns, Principals at Philip Ormonde Fitzpatrick, discuss the gene editing IP landscape alongside Scott Douglas, Vice President of Intellectual Property at Editas, and Nicole Mastrangelo, IP Counsel at The Broad Institute of MIT and Harvard.The conversation tackles the current state of CRISPR patent disputes and their implications for commercialisation, alongside claiming strategies designed to protect emerging base and prime editing technologies. The panel considers how to differentiate innovations in such a heavily saturated space.Attention is also given to the growing use of click-wrap and labelling licenses for accessing CRISPR tools, examining compliance and enforceability. The session contrasts theoretical freedom-to-operate with practical freedom-to-action, offering licensing and indemnity strategies to manage exposure when clearing every patent risk isn't feasible.